Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;42(1):102-122.
doi: 10.1080/10790268.2018.1439803. Epub 2018 Feb 27.

Spinal cord injury pharmacotherapy: Current research & development and competitive commercial landscape as of 2015

Jason R Guercio  1 , Jason E Kralic  2 , Eric J Marrotte  3 , Michael L James  3   4
Affiliations
Review

Spinal cord injury pharmacotherapy: Current research & development and competitive commercial landscape as of 2015

Jason R Guercio et al. J Spinal Cord Med. 2019 Jan.

Abstract

Context: Current treatment of spinal cord injury (SCI) focuses on cord stabilization to prevent further injury, rehabilitation, management of non-motor symptoms, and prevention of complications. Currently, no approved treatments are available, and limited treatment options exist for symptoms and complications associated with chronic SCI. This review describes the pharmacotherapy landscape in SCI from both commercial and research and development (R&D) standpoints through March 2015.

Methods: Information about specific compounds has been obtained through drug pipeline monographs in the Pharmaprojects® (Citeline, Inc., New York, New York, USA) drug database (current as of a search on May 30, 2014), websites of individual companies with compounds in development for SCI (current as of March 24, 2015), and a literature search of published R&D studies to validate the Pharmaprojects® source for selected compounds (current as of March 24, 2015).

Results: Types of studies conducted and outcomes measured in earlier phases of development are described for compounds in clinical development Currently four primary mechanisms are under investigation and may yield promising therapeutic targets: 1) neuronal regeneration; 2) neuroprotection (including anti-inflammation); 3) axonal reconnection; and 4) neuromodulation and signal enhancement. Many other compounds are no longer under investigation for SCI are mentioned; however, in most cases, the reason for terminating their development is not clear.

Conclusion: There is urgent need to develop disease-modifying therapy for SCI, yet the commercial landscape remains small and highly fragmented with a paucity of novel late-stage compounds in R&D.

Keywords: Clinical trials; Pharmacotherapy; Spinal cord injury.

PubMed Disclaimer

References

    1. Dasari VR, Veeravalli KK, Dinh DH.. Mesenchymal stem cells in the treatment of spinal cord injuries: A review. World J Stem Cells 2014;6(2):120–33. - PMC - PubMed
    1. Navarro R, Juhas S, Keshavarzi S, Juhasova J, Motlik J, Johe K, et al. . Chronic spinal compression model in minipigs: a systematic behavioral, qualitative, and quantitative neuropathological study. J Neurotrauma 2012;29(3):499–513. - PMC - PubMed
    1. Scivoletto G, Tamburella F, Laurenza L, Molinari M.. Distribution-based estimates of clinically significant changes in the International Standards for Neurological Classification of Spinal Cord Injury motor and sensory scores. Eur J Phys Rehabil Med 2013;49(3):373–84. - PubMed
    1. Sekhon LH, Fehlings MG.. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 2001;26(24 Suppl):S2–12. - PubMed
    1. Ditunno JF Jr., Young W, Donovan WH, Creasey G.. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994;32(2):70–80. - PubMed

MeSH terms